Vivek Subbiah

Sarah Cannon Research Institute

Full Professor(heuristic)

Cancer Genomics and Diagnostics · Cancer Research

h-index79

i10-index405

Publications1,434

Citations32,181

Grants

4 total · 1 active

NIH #1R01CA273168-01

Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold

Active

Amount: $612K
Period: 2022-07-01 → 2027-06-30
PIs: 3
Est. capacity / PI: ~0 students

Awarded at UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR

NIH #5R01CA242845-03

Blocking tumor progression in therapy-responsive RET aberration-associated cancer

Amount: $383K
Period: 2020-09-01 → 2025-05-31
PIs: 3
Est. capacity / PI: ~0 students

Awarded at UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR

NIH #5R01CA242845-02

Blocking tumor progression in therapy-responsive RET aberration-associated cancer

Amount: $391K
Period: 2020-09-01 → 2025-05-31
PIs: 3
Est. capacity / PI: ~0 students

Awarded at UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

All Grants

4 total · 1 active

NIH #1R01CA273168-01

Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold

Active

Amount: $612K
Period: 2022-07-01 → 2027-06-30
PIs: 3
Est. capacity / PI: ~0 students

Awarded at UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR

NIH #5R01CA242845-03

Blocking tumor progression in therapy-responsive RET aberration-associated cancer

Amount: $383K
Period: 2020-09-01 → 2025-05-31
PIs: 3
Est. capacity / PI: ~0 students

Awarded at UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR

NIH #5R01CA242845-02

Blocking tumor progression in therapy-responsive RET aberration-associated cancer

Amount: $391K
Period: 2020-09-01 → 2025-05-31
PIs: 3
Est. capacity / PI: ~0 students

Awarded at UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR

NIH #1R01CA242845-01A1

Blocking tumor progression in therapy-responsive RET aberration-associated cancer

Amount: $414K
Period: 2020-09-01 → 2025-05-31
PIs: 3
Est. capacity / PI: ~0 students

Awarded at UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR

Lab Funding Health

Find elsewhere

Institution / lab homepage Search on ResearchGate

In-Field Influence

0.0032

PageRank within Cancer Research co-authorship network

Explore collaboration map

Admission Signals

New paper: Beyond one gene, one target: Next-generation precision oncology (Trends in cancer)2026-06-01
New NIH award: $612K — Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold2022-07-01

Data Freshness

Publications as of 2026-07-01
Grants as of 2026-06-30

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

ORCID: 0000-0002-6064-6837

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 169

Beyond one gene, one target: Next-generation precision oncology
Trends in cancer · 2026-06-01
First data disclosure from the first-in-human phase 1/2 trial of SMP-3124LP, the first investigational pegylated liposome CHK1 inhibitor, in patients with selected advanced solid tumors.
Journal of Clinical Oncology · 2026-05-27
A phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) monotherapy in patients with selected advanced or metastatic solid tumors: First disclosure of clinical data.
Journal of Clinical Oncology · 2026-05-27
A Performance and Quality Improvement Intervention Integrating Molecular Testing to Support Personalized Cancer Care in Lung and Thyroid Cancers
Advances in Cancer Education and Quality Improvement · 2026-04-01
Reconsidering Asparaginase in Leukemia Therapy
Acta Haematologica · 2026-03-13
Supplementary Table S3 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
2025-12-24
Supplementary Table S17 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
2025-12-24
Supplementary Table S10 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
2025-12-24
Data from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
2025-12-24
Table 2 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
2025-12-24
Supplementary Table S7 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
2025-12-24
Supplementary Table S13 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
2025-12-24
Supplementary Table S8 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
2025-12-24
Figure 3 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
2025-12-24
Supplementary Table S2 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
2025-12-24
Supplementary Table S5 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
2025-12-24
Supplementary Figure S1 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
2025-12-24
Supplementary Table S1 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
2025-12-24
Table 3 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
2025-12-24
Supplementary Figure S4 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
2025-12-24

Open author page on OpenAlex →